Altimmune Inc. (ALT) and Translate Bio Inc. (NASDAQ:TBIO) Comparing side by side

Both Altimmune Inc. (NASDAQ:ALT) and Translate Bio Inc. (NASDAQ:TBIO) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Altimmune Inc. 3 3.11 N/A -22.68 0.00
Translate Bio Inc. 9 175.34 N/A -2.17 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Altimmune Inc. and Translate Bio Inc.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Altimmune Inc. 0.00% -103.4% -77%
Translate Bio Inc. 0.00% 0% -47.9%

Liquidity

Altimmune Inc.’s Current Ratio and Quick Ratio are 8.7 and 8.7 respectively. The Current Ratio and Quick Ratio of its competitor Translate Bio Inc. are 10.5 and 10.5 respectively. Translate Bio Inc. therefore has a better chance of paying off short and long-term obligations compared to Altimmune Inc.

Analyst Ratings

In next table is delivered Altimmune Inc. and Translate Bio Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Altimmune Inc. 0 0 0 0.00
Translate Bio Inc. 0 0 1 3.00

Meanwhile, Translate Bio Inc.’s consensus target price is $21, while its potential upside is 106.90%.

Institutional and Insider Ownership

Institutional investors owned 6.8% of Altimmune Inc. shares and 59.9% of Translate Bio Inc. shares. Insiders owned 2.4% of Altimmune Inc. shares. Competitively, 31.15% are Translate Bio Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Altimmune Inc. -11.71% -12% -13.44% -28.84% -83.08% 28.16%
Translate Bio Inc. 11.68% -8.11% 41.19% 60.31% 0% 38.93%

For the past year Altimmune Inc.’s stock price has smaller growth than Translate Bio Inc.

Summary

Translate Bio Inc. beats Altimmune Inc. on 8 of the 8 factors.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, designs and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. Its preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others. The company was formerly known as Vaxin Inc. Altimmune, Inc. was founded in 1997 and is based in Gaithersburg, Maryland.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.